Puma Biotechnology
What Happened To Puma Biotechnology?
Puma Biotechnology, Inc. - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS
Puma Biotechnology - Crunchbase Company Profile & Funding
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Articles with Puma Biotechnology
News Release
Puma Biotechnology Reports First Quarter 2021 Financial Results
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology, Inc. - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
News Release
Puma Biotechnology: Increasing Our Exposure (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
Puma Biotechnology Announces Upsizing and Pricing of $120 Million Public Offering of Common Stock
Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
